<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-ELVRNDY9</identifier><date>2021</date><creator>Azarija, Jelena</creator><relation>documents/doc/E/URN_NBN_SI_doc-ELVRNDY9_001.pdf</relation><relation>documents/doc/E/URN_NBN_SI_doc-ELVRNDY9_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 30-32</format><identifier identifier_type="COBISSID_HOST">88074499</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-ELVRNDY9</identifier><language>slv</language><publisher publisher_location="Ljubljana">Združenje za radioterapijo in onkologijo SZD</publisher><source>Pregled in novosti v onkologiji (2021)</source><rights>BY-NC-ND</rights><subject language_type_id="slv">obsevanje</subject><subject language_type_id="slv">onkološko zdravljenje</subject><subject language_type_id="slv">radioterapija</subject><title>Is adjuvant chemotherapy in early hormone receptor positive HER2-negative breast cancer reality</title><title>Je adjuvantna kemoterapija pri zgodnjem hormonsko odvisnem HER2-negativnem raku dojke realnost</title></Record>